Articles Tagged With:
-
Nearly Half of the Uninsured are Eligible for Medicaid or Obamacare
Nearly half of the 32.3 million nonelderly people in the US who didn’t have health insurance at the beginning of this year are eligible for Medicaid or subsidized coverage through the ACA.
-
Incidental findings in research subjects: It’s complicated
Incidental findings in research subjects — which can be completely benign or herald significant health problems — raise thorny issues for IRBs that are best addressed through informed consent and a detailed contingency plan.
-
Comments, concerns on ANPRM draft may forecast NPRM reaction
A recently published analysis of comments on biospecimen research submitted in response to the 2011 Advance Notice of Proposed Rulemaking indicates institutional review boards and researchers are facing a series of “tradeoffs” that will likely carry over in the next iteration of the human research Common Rule.
-
Pediatric Hematologic Emergencies
MONOGRAPH: In-depth disorders of the hemogram: red blood cells, platelets, and white blood cells.
-
Changes to Common Rule would change exemptions
The NPRM of the Common Rule in human research protection provides for eight categories of exemption to IRB reviews and discusses a tool that investigators and others could use to determine whether a study is exempt.
-
IC under revised Common Rule is transparent, tightened
Common Rule changes under the Notice of Proposed Rulemaking could impact how IRBs handle the informed consent process, by both increasing transparency and imposing stricter new requirements about information provided to prospective subjects.
-
Shaking the IRB Foundation
“I think the local IRB has seen its day."
-
Between-arm Differences in BP Predict Peripheral Arterial Disease
An inter-arm systolic blood pressure difference of as little as 10 mmHg was associated with a doubling of the risk for peripheral arterial disease.
-
Uric Acid as a Predictor of Hypertension
Our currently defined levels of “normal” for uric acid may have to be reconsidered.
-
ACE Inhibitors vs ARBs for Hypertension
This data review would support using angiotensin-converting-enzyme inhibitors preferentially over angiotensin II receptor blockers in most patients with hypertension.